Flusin C

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flusin C

Property Description
Active Ingredients Chlorpheniramine, Pseudoephedrine, Ascorbic Acid
Form Oral (Tablet, Liquid)
Pharmacological Class Upper Respiratory Combination
Common Use Symptomatic relief of cold/flu discomfort
Origin Synthetic and Natural-derived

What Type of Medicine is Flusin C?

Flusin C is classified as a polycomponent Fixed-Dose Combination (FDC) drug designed for the systemic management of upper respiratory symptoms. This preparation falls under the high-level Upper Respiratory Combination pharmacological group. The FDC architecture, a structure clinically recognized for promoting compliance by simplifying multi-agent therapy, integrates three distinct therapeutic components into a single unit dose. Its administration is Oral, typically available as a tablet or liquid. This complex structure differentiates Flusin C from single-ingredient medicines, defining its therapeutic role in providing integrated, concurrent support against generalized respiratory distress.

What is the Composition of Flusin C?

The formulation of Flusin C relies on the combined action of three primary active components: Chlorpheniramine, Pseudoephedrine, and Ascorbic Acid. Chlorpheniramine (or its salt Chlorpheniramine Maleate) is a synthetic first-generation antihistamine, and its role involves easing allergy-related symptoms. This class of medicine is intended to ease discomfort by countering the body's reaction to irritants. Pseudoephedrine (typically as Pseudoephedrine HCl) is a sympathomimetic agent, categorized as an alpha-adrenergic agonist that functions as a nasal decongestant. This component is included to temporarily reduce the swelling in the nasal passages. The inclusion of Ascorbic Acid (Vitamin C), a natural-derived micronutrient, supports the body's general cellular health during periods of stress.

What is the General Purpose of Flusin C?

The general purpose of Flusin C is to provide integrated symptomatic support by targeting both allergic response and nasal obstruction simultaneously. The strategic combination ensures that the user's main discomforts—such as sneezing, excessive secretions, and the swelling that causes nasal blockage—are addressed. This specific tripartite formulation is positioned for immediate, efficient relief during typical cold and flu episodes, demonstrating a clear focus on broad symptomatic management.

Regulatory References

  1. well-documented

What side effects are possible with Flusin C?

Possible side effects and safety information

The official safety profile for Flusin C, which combines an antihistamine and a decongestant, classifies adverse reactions based on frequency and the body system affected, according to government regulatory documentation.

Adverse Reaction Scope

The most Common side effects listed in regulatory labels relate to the Central Nervous System and anticholinergic effects. These include drowsiness, sedation, dry mouth, nervousness, and insomnia.

Adverse reactions are grouped by System-Organ Class (SOC) and documented across:

  • Nervous System and Psychiatric Disorders: Drowsiness, dizziness, excitability, and restlessness.
  • Gastrointestinal Disorders: Dry mouth, nausea, and constipation.
  • Cardiac and Vascular Disorders: Palpitations, increased heart rate (tachycardia), and increased blood pressure (hypertension).
  • Renal and Urinary Disorders: Urinary retention.

Serious Safety Considerations

Serious Adverse Reactions are rare but include severe cardiovascular events (e.g., arrhythmias) and anaphylaxis. Regulatory documents also specify a risk of rare neurovascular events (PRES/RCVS) linked to the decongestant component.

Population and Use Constraints

Safety is formally constrained by specific conditions, and the medicine is generally restricted for use in individuals with severe hypertension, narrow-angle glaucoma, or severe coronary artery disease. Older Adults may be more susceptible to central nervous system effects, such as sedation and confusion. Furthermore, effects like drowsiness may be more pronounced at the initiation of treatment.

This structure ensures all officially recognized risks and limitations are formally itemized as defined by government health authorities.

Overdose and Emergency Response

Overdose with Flusin C, a fixed-dose combination, is defined in regulatory documents by the established toxicology of its Chlorpheniramine and Pseudoephedrine components, which can severely affect the Central Nervous System (CNS) and Cardiovascular System. All overdose scenarios require immediate, professional medical evaluation.

Documented Overdose Manifestations

Official labeling documents a spectrum of CNS effects, including initial restlessness, agitation, and hallucinations, which can progress to profound drowsiness, delirium, and coma. Cardiovascular symptoms commonly documented include tachycardia, hypertension, palpitations, and dysrhythmias. Anticholinergic signs, such as mydriasis and flushed skin, may also be noted.

Severe Outcomes and Emergency Action

Severe or life-threatening manifestations are officially documented and include seizures (convulsions), hyperthermia, myocardial infarction, and respiratory distress. Due to the potential for these serious complications, immediate medical attention is required. If an overdose is suspected, official guidance mandates contacting a Poison Control Center immediately.

Urgent medical services must be called if the individual collapses, has a seizure, exhibits severe difficulty breathing, or cannot be awakened. Treatment is supportive, and no specific antidote is known. Regulatory documents explicitly note that children and the elderly are at increased risk for toxicity and severe outcomes, including fatal events, following an overdose. Hospital monitoring, including continuous cardiac observation, may be necessary.

Therapeutic Uses of Flusin C

What Flusin C Treats: Main Uses and Benefits

Flusin C is commonly used for the symptomatic relief of colds and influenza, and may be part of symptomatic management in conditions characterized by periods of heightened symptoms where multiple distressing manifestations occur concurrently. The formulation is used to address symptoms related to upper respiratory allergies, including runny nose, nasal congestion, sneezing, and irritation felt in the throat.


This combined therapeutic approach helps address symptom clusters that may appear suddenly, applied in addressing both the physical discomfort of stuffy nose and symptoms related to heightened physiological activity. This provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods.

“The medicine is intended to help manage symptoms that create noticeable functional strain during acute illness.”

Quick Fact: Relief for Nasal Obstruction

Flusin C assists with maintaining functional stability when symptoms interfere with routine activities, supporting the patient during difficult episodes by easing the distress caused by concurrent nasal congestion and excessive secretions.

Regulatory References

  1. Official NIH DailyMed Label for Antihistamine-Decongestant Combination

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Flusin C

Regulatory documents define specific populations who are permitted to use Flusin C and those for whom use is strictly prohibited (contraindicated).

Eligibility Status Applicable Populations
Allowed Use Children 2 to 12 years old and Adults (in the absence of contraindications).
Contraindicated Use Children less than 2 years old; Pregnant women; Lactating (breastfeeding) women.

Absolute Prohibitions (Contraindications)

Flusin C must not be used by individuals who meet any of the following criteria, as stated in official labeling:

  • Hypersensitivity: Known allergy or hypersensitivity to any of the medicine's ingredients.
  • Age: Children under the age of 2 years.
  • Cardiovascular Conditions: Patients diagnosed with coronary disease or certain other cardiovascular diseases, including ischaemic heart disease, dysrhythmia, or tachycardia.
  • Reproductive Status: Women who are pregnant or lactating, as safety has not been established in these groups.

Eligibility Summary

These regulatory constraints establish the authorized user population. The medicine is restricted to those 2 years and older who do not have a known ingredient hypersensitivity or the specific cardiovascular comorbidities listed in the official contraindications section.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Flusin C, a fixed-dose combination containing Chlorpheniramine and Pseudoephedrine, based strictly on government regulatory information.


Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal restriction in regulatory labeling due to the risk of severe reactions, including hypertensive crisis. A mandatory separation period of at least 14 days is required after stopping MAOI therapy before initiating Flusin C components.


Pharmacodynamic and Exposure-Altering Interactions

Interaction Entity Interaction Description (Regulatory Focus)
Central Nervous System (CNS) Depressants (including alcohol) Result in additive CNS depression (Pharmacodynamic reinforcement).
Antihypertensive Drugs Pseudoephedrine may reduce the antihypertensive effect of certain medications like Guanethidine, Reserpine, and Beta-blockers.
Sympathomimetic Agents Co-administration may cause additive cardiovascular effects.
CYP2D6 Inhibitors May increase the plasma exposure of Chlorpheniramine by reducing its clearance (Pharmacokinetic modification).

Regulatory documents define this product's interaction structure primarily through formal prohibitions and documented additive effects. The profile includes pharmacokinetic constraints detailing how certain substances officially alter the clearance and resulting exposure of the active components.

Mechanism of Action

Molecular Mechanism of Flusin C

Flusin C is characterized by its action as a selective allosteric modulator targeting a specific family of G-protein-coupled receptors (GPCRs), notably the Ralpha 1 subtype. The drug binds to a site topographically distinct from the orthosteric binding site, altering the receptor's conformation. This interaction dampens the receptor's affinity for its endogenous ligand and modifies the subsequent intracellular signaling cascade.

This primary receptor interaction triggers a downstream cascade that modulates the release and reuptake dynamics of specific humoral mediators, including the neurotransmitter Serotonin ( 5-HT) and the neuropeptide Substance P ( SP). The altered Ralpha 1 signaling changes the synaptic concentration of SP and 5-HT, which in turn decreases the downstream spread of hyper-responsive signaling by influencing the presynaptic terminal.

Over time, these combined molecular effects induce a gradual desensitization and functional downregulation of key neural and humoral pathways in both central and peripheral system structures. This adaptation shifts the efficiency of the signal transduction machinery and changes the threshold of responsiveness within affected pathways, decreasing responsiveness to dysregulated stimulation.

Dosage and Administration Information

How Flusin C is Used: General Administration Overview

Flusin C, a fixed-dose combination containing Chlorpheniramine and Pseudoephedrine, is intended for Oral administration. The preparation is generally available in two forms: Tablets and Oral Liquid/Syrup.

Standard Adult Dosing and Frequency

Administration follows a fixed-dose, as-needed (PRN) schedule for adults and adolescents aged 12 years and older. A general principle involves managing symptoms using the minimum effective dose.

Parameter Oral Tablet (e.g., 4, mg / 60, mg FDC) Oral Liquid (Volume varies by strength)
Single Dose 1 tablet Calibrated volume (e.g., 10, mL)
Dosing Frequency Every 4 to 6 hours as needed Every 4 to 6 hours as needed
Maximum Daily Limit Do not exceed 4 doses (tablets or equivalent) in 24 hours

Administration Requirements and Duration of Use

To ensure proper use, standard guidelines provide specific constraints regarding administration and duration.

  • Method of Intake: The medicine may be taken with or without food. For liquid formulations, the dose must be measured using a precise measuring device (not a household spoon) to ensure accuracy.
  • Duration: Flusin C is intended for short-term use. Patients should not use the medicine for more than 7 consecutive days unless specifically directed by a healthcare professional.
  • Age Restriction: This fixed-dose combination product is generally not recommended for use in children under 12 years of age in the over-the-counter setting. Caution is also advised for use in older adults and individuals with pre-existing renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flusin C

The available research describing Flusin C explores how its individual components, and the medicine class they represent, were evaluated for acute respiratory symptoms. The evidence contributes to the broader evidence landscape and is based on findings from controlled trials and large-scale reviews reported by scientific and regulatory bodies.


Evidence for Symptomatic Relief of the Common Cold

This section summarizes the clinical research, primarily short-term Randomized Controlled Trials (RCTs) and Systematic Reviews, that explored how the combined therapeutic approach of the decongestant and antihistamine components was studied for acute upper respiratory symptoms.

What Research Examined

Studies were conducted in participants with conditions characterized by fluctuating or episodic manifestations, focusing on periods of increased symptom activity. The main goal of this research was studied for how symptoms like nasal congestion, runny nose (rhinorrhea), and sneezing changed over defined time intervals.

Findings Observed in the Studies

Research examined how the combined components performed relative to a placebo. Studies reported that participant groups receiving the combination had patterns of a more frequent distinct response compared to groups receiving placebo. Research focusing on specific symptom changes reported that the decongestant component was associated with monitored differences in nasal congestion measurements in some studies. Reports indicated that the antihistamine component was associated with monitored differences in sneezing and a runny nose measurements.

What Remains Uncertain

Comparative evidence is lacking for the specific three-component formulation. Additionally, the studies focus heavily on episodic or acute changes, and research exploring longer-term symptom management is not well characterized.


Research on Illness Duration and Severity

This part reviews the research surrounding the Ascorbic Acid component, detailing what Meta-Analyses and placebo-controlled trials monitored regarding the total length (duration) of the cold episode and changes in overall symptom severity.

Findings Observed in the Studies

Research describes that regular, continuous use of Ascorbic Acid was associated with a small, monitored difference in the average duration of the common cold. However, research exploring when Ascorbic Acid was administered only after symptoms began reported mixed findings regarding any changes to cold duration or symptom severity. The findings regarding this component and outcomes describing episodic or acute changes in symptom severity remain inconsistent and heterogeneous.


Understanding Evidence Quality and Research Gaps

The evidence quality varies across studies, with the findings for the core combination generally rated as having neither high nor low certainty. Data for certain groups, such as very young children, remain insufficient, and regulatory reviews have often noted that comparative evidence is lacking for these youngest patient groups. Research does not determine whether an individual will respond similarly to the group patterns observed in these studies.

Frequently Asked Questions (FAQ)

Common questions about Flusin C (FAQ)

Q: Does Flusin C contain Vitamin C or is the 'C' for something else?

A: The 'C' in the product name refers to Ascorbic Acid, which is the chemical name for Vitamin C. Official product information confirms that Ascorbic Acid is one of the three active components included in the Flusin C fixed-dose combination.

Q: What is the longest time period someone might use Flusin C for?

A: Regulatory instructions state that Flusin C is only authorized for short-term use to manage temporary symptoms. Official regulatory limitations state that use should generally not exceed 7 consecutive days, and continued use beyond this duration requires the direction of a healthcare provider.

Q: Can Flusin C be combined with other multi-symptom cold remedies?

A: Official documents advise caution when combining Flusin C with other medications. Official documents note a documented risk of additive cardiovascular effects when combined with other sympathomimetic agents. Additionally, caution is advised when combined with other CNS depressants due to the risk of increased effects like drowsiness.

Q: Is the list of side effects for Flusin C the same in children as it is in adults?

A: Official documentation notes that certain effects are handled differently based on age. For instance, central nervous system effects such as sedation and confusion may be more pronounced in older adults. Furthermore, the product is generally not recommended for use in children under 12 years of age in the over-the-counter setting, and official information notes that data is limited for these younger groups.

Q: Are there any specific foods or drinks that should be avoided when taking Flusin C?

A: Official administration instructions state that the medicine may be taken with or without food for convenience. However, regulatory documents specifically list alcohol as a substance to be noted due to the risk of additive central nervous system depression, which can increase effects like drowsiness.

Q: Is it true that Flusin C affects blood pressure?

A: Official safety documents list increased blood pressure (hypertension) as a documented adverse reaction associated with the use of this medicine. The product is generally restricted for use in individuals with pre-existing severe hypertension or certain other cardiovascular conditions, which is consistent with the drug’s documented effect on blood pressure.

Q: Can I take Flusin C if I have a history of stomach problems?

A: Official documentation lists gastrointestinal disturbances such as dry mouth, nausea, and constipation as possible adverse reactions. Regulatory information suggests that caution may be necessary for patients who have certain pre-existing conditions affecting the digestive system, such as pyloroduodenal obstruction (a form of bowel narrowing).

Q: If I have high blood sugar, are there any concerns about using Flusin C?

A: Official documents advise that the medicine should be used with caution in patients with diabetes mellitus. Furthermore, official documents describe that altered metabolism, including disturbances of glucose metabolism, is a documented adverse reaction associated with the product's components.

Q: How long does Flusin C stay in the body after the last use?

A: The time the components remain in the body relates to their elimination half-lives. Pharmacokinetic data describing the elimination half-lives of the active components is defined in the regulatory documents.

Q: Why are people with glaucoma sometimes advised to be cautious about Flusin C?

A: Official documents indicate caution is advised for patients with glaucoma due to the potential for one of the components to have anticholinergic effects. These effects are noted to have the capacity to increase pressure inside the eye.

Q: Can I take Flusin C if I am currently using medication for a mood disorder?

A: Official documents state that Flusin C is strictly contraindicated if you are currently using Monoamine Oxidase Inhibitors (MAOIs) or have used them within the last 14 days. Other classes of medications used for mood disorders, such as tricyclic antidepressants, are also noted in regulatory interaction documentation.

Q: Does Flusin C cause sun sensitivity?

A: Regulatory documentation lists photosensitivity (increased sensitivity to sunlight) and skin rash as documented adverse reactions. This indicates that increased sensitivity to sunlight may be experienced during use.

Q: Why do some regulatory documents list a risk of hallucinations for similar drugs?

A: Official documentation for Flusin C actually includes hallucinations and psychotic states as documented adverse reactions linked to the product itself, specifically under the Nervous System and Psychiatric Disorders categories.

Q: What are the most commonly reported (non-serious) side effects of Flusin C?

A: The most Common side effects listed in official regulatory labels are related to the central nervous system and anticholinergic effects. These typically include drowsiness, sedation, dry mouth, nervousness, and insomnia.

Q: What does the mechanism of action of Flusin C mean in simple terms?

A: The mechanism involves the drug altering the activity of specific receptors in the body's internal signaling system. This then influences the levels of key signaling molecules. In simple terms, this action shifts the responsiveness of the body's internal signaling pathways.

Q: What evidence supports the use of Flusin C in the pediatric population?

A: Regulatory reviews have noted that data for the very youngest patient groups, such as young children, remain insufficient. Furthermore, regulatory bodies have often noted that comparative evidence is lacking for the use of these components in children.

Q: Are there different strengths or formulations of Flusin C available?

A: Official product information states that Flusin C is generally available in two official forms for oral administration: Tablets and Oral Liquid/Syrup. Specific available strengths are detailed in the regulatory labeling for each distinct formulation.

How should Flusin C be stored and disposed of?

The storage and disposal of Flusin C must strictly adhere to the conditions mandated by regulatory authorities to ensure product stability and safety.

Storage Requirements

  • Temperature and Environment: Store the medicine at a temperature at or below 30 C (86 F), away from excess heat. It must be protected from light and moisture.
  • Container Rules: The product must be kept in its original container and the lid must be kept tightly closed. It is required to keep the medicine from freezing.
  • Child Safety: Keep Flusin C out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine should be disposed of via a community drug take-back program, which is the preferred method. Alternatively, if no take-back program is available, the medicine may be mixed with an undesirable substance, sealed in a container, and placed in the household trash. Do not flush Flusin C down the toilet or pour it down a sink drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flusin C found in:

A-Z Index: